TCDA Tricida Inc

Tricida, Inc., a late-stage pharmaceutical company, focuses on developing therapeutics to address renal, metabolic, and cardiovascular disease. Its lead product candidate, TRC101, a non-absorbed orally-administered polymer drug that is in Phase III clinical trials used to treat metabolic acidosis in patients with chronic kidney disease. The company was founded in 2013 and is headquartered in South San Francisco, California.

$4.71
As of 03/03/2021     IEX book   CBOE book


Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Quarterly filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
Common stocks
Micro cap
Health Care
Drug Manufacturers—Specialty &
USA
USA
06/28/2018
50,244,465
1,202,067
$237,153,875
0.00%
SEC Edgar Online
10-Q
10-K
89610F101
US89610F1012
BYZMG55

Valuation   (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
0.00
1.47
0.00
-243.22%
0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy